

## Freedom of Information request 476-23

---

### Request & Response

I am researching the incidence and treatment of breast cancer. I would greatly appreciate if you could answer the following question.

1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

• Abemaciclib + Aromatase Inhibitor* or Fulvestrant	<5
• Anthracycline (e.g. doxorubicin or epirubicin) as a single agent	0
• Atezolizumab +Nab-paclitaxel/Paclitaxel	0
• Capecitabine as a single agent	12
• Eribulin as a single agent or in combination	0
• Everolimus + Exemestane	0
• Fulvestrant as a single agent	<5
• TK Inhibitors (Neratinib/Lapatinib)	0
• Parp Inhibitors (Olaparib/Talazoparib)	0
• Palbociclib + Aromatase Inhibitor* or Fulvestrant	14
• Pembrolizumab	<5
• Platinum (e.g. carboplatin or cisplatin) as a single agent	0
• Ribociclib + Aromatase Inhibitor* or Fulvestrant	12
• Sacituzumab Govitecan	<5
• Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	11
• Taxane and/or Anthracycline in combination	0
• Trastuzumab as a single agent or in combination	6
• Trastuzumab conjugates (Trastuzumab emtansine, Trastuzumab deruxtecan)	<5
• Any other active systemic anti-cancer therapy	29

\*aromatase Inhibitors include anastrozole, exemestane and letrozole

2. Does your trust participate in any clinical trials for the treatment of breast cancer? If so, please provide the name of each trial and the number of patients taking part.

- Appalache **<5 patients**
- Add Aspirin **19 patients**
- HER2 radical **0 patients**

As the number of events in some areas are very small and in accordance with the Code of Practice for Official Statistics any number that is less than five, actual numbers and potentially identifiable information is

withheld to help maintain patient confidentiality due to potential risk of disclosure. Further information is available in the [ISD Statistical Disclosure Control Protocol](#).

If you are not satisfied with the way your request has been handled or the decision given, you may ask NHS Borders to review its actions and the decision. If you would like to request a review please apply in writing to, Freedom of Information Review, NHS Borders, Room 2EC3, Education Centre, Borders General Hospital, Melrose, TD6 9BS or [foi.enquiries@borders.scot.nhs.uk](mailto:foi.enquiries@borders.scot.nhs.uk).

The request for a review should include your name and address for correspondence, the request for information to which the request relates and the issue which you wish to be reviewed. Please state the reference number **476-23** on this request. Your request should be made within 40 working days from receipt of this letter.

If following this review, you remain dissatisfied with the outcome, you may appeal to the Scottish Information Commissioner and request an investigation of your complaint. Your request to the Scottish Information Commissioner should be in writing (or other permanent form), stating your name and an address for correspondence. You should provide the details of the request and your reasons for dissatisfaction with both the original response by NHS Borders and your reasons for dissatisfaction with the outcome of the internal review. Your application for an investigation by the Scottish Information Commissioner must be made within six months of your receipt of the response with which you are dissatisfied. The address for the Office of the Scottish Information Commissioner is, Office of the Scottish Information Commissioner, Kinburn Castle, Doubledykes Road, St Andrews, Fife.